Glaxosmithkline Intellectual Property Development Limited

Praecis Pharmaceuticals, Inc.

Ghotas Evindar

David I Israel

Oliver Schon

Hongfeng Deng

Peter Kumpalume

Christine Patricia Donahue

David Paolella

Letian Kuai

Ninad V Prabhu

Barry A Morgan

Martha Alicia De La Rosa

Ashis K Saha

Wieslaw Mieczyslaw Kazmierski

Malcolm J Kavarana

Vicente Samano

Gang Yao

Yoshiaki Washio

John Franklin Miller

Sylvie Bernier

Aaron Coffin

Hongfang Yang

Alexander L Satz

Bing Xia

Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. 

Modulators of indoleamine 2,3-dioxygenase

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

Compounds for affinity chromatography and for extending the half-life of a therapeutic agent

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.

Sphingosine-1-phosphate (SIP) receptor agonists

The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.

Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity

Growing community of inventors

Waltham, MA, United States of America

Ghotas Evindar